课题基金 / 基金详情

项目摘要

项目成果

Shunqiang Li的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The PDX Core is the epicenter of the WU-PDTC as it will be responsible for the development, organization, characterization, storage, and dissemination of high quality pathogen free PDX models for research projects investigating anticancer agents, within and outside of WU-PDTC. The PDX Core builds on outstanding existing infrastructure and expertise at Washington University School of Medicine (WUSM). The Human and Mouse Linked Evaluation of Tumors (HAMLET) PDX Core at the Institute of Clinical and Translational Study (ICTS) and the Solid Tumor Tissue Bank and Registry (STTBR) led by Drs. Li and Fields, respecitvely, have a proven record of success in generating PDX models from a wide variety of cancers and in utilizing these models for drug testing. Between these programs, we have already generated over 449 PDX models across more than 12 cancer types, from the most common cancers, such as breast, lung, and colorectal, to rare cancers, such as sarcomas and lymphomas. These existing models will become part of the new WU-PDTC, where about 1000 new PDX models will be developed and added to this collection. The new PDX models will further enhance our capability to support ongoing projects and open new opportunities for research in rare cancer types. Taking advantage of the strong proteogenomic capability within the proposed WU-PDTC and WUSM, we will expand the characterization of these PDX models to include both whole exome sequencing and RNA-Seq, providing investigators with a more comprehensive picture of the mutational profiles, the molecular signatures, clonal structures, and heterogeneities of the models to help with cancer sub-typing and target selection. Besides research projects at WU-PDTC, PDX models in the PDX Core collection will also be shared with other PDTCs and made broadly available to authorized non-network investigators. Furthermore, the PDX Core will study new approahes to improve the take rate, fidelity, and characterization of PDX models. The large patient base and exceptionally strong institutional backing, including matching funds, will additionally ensure that these goals are achievable.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of resistance to CDK4/6 inhibitor in breast cancer
  • 批准号:
    10560131
  • 项目类别:
  • 资助金额:
    $65.05万
  • 财政年份:
    2023
  • 负责人:
    Shunqiang Li
  • 依托单位:
PDX Core
  • 批准号:
    10005282
  • 项目类别:
  • 资助金额:
    $2.01万
  • 财政年份:
    --
  • 负责人:
    Shunqiang Li
  • 依托单位:
PDX Core
  • 批准号:
    10005284
  • 项目类别:
  • 资助金额:
    $2.01万
  • 财政年份:
    --
  • 负责人:
    Shunqiang Li
  • 依托单位:
国内基金
海外基金
患者依从性与脑卒中后跌倒风险相关性及“Teach-Back ”护理干预效应研究
  • 批准号:
    2026JJ81464
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    叶婷
  • 依托单位:
基于Teach-back药学科普模式的慢阻肺患者吸入用药依从性及疗效研究
  • 批准号:
    2024KP61
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    余丹
  • 依托单位:
基于Quench-Back保护的超导螺线管磁体失超过程数值模拟研究
  • 批准号:
    51307073
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    25.0万元
  • 批准年份:
    2013
  • 负责人:
    郭兴龙
  • 依托单位: